A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Primary Objectives: IVS-3001 is an autologous CAR-T cell therapy targeting human leukocyte antigen (HLA-G) * Phase 1: To determine the safety, tolerability and the recommended phase 2 dose (RP2D) of IVS-3001 in subjects with refractory or relapsed HLA-G+ solid tumors. * Phase 2a: To evaluate the anti-tumor activity of IVS-3001 in selected HLA-G+ solid tumor types. Secondary Objectives: * To evaluate pharmacokinetic profile of IVS-3001: persistence, expansion. * To evaluate the clinical activity of IVS-3001 in selected HLA-G+ solid tumor types. * To assess the long-term safety of IVS-3001. Exploratory Objectives: • To explore functionality of IVS-3001 as well as immune biomarkers linked with IVS-3001 and their relationship with clinical response